Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin + Ara-C +/- Bevacizumab in Untreated AML
NCT00096148Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Nov 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Oct 2004; status: terminated.
02
Drugs
bevacizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00096148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096148.